Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Atreca reports cash, equivalents of $182.3M at June 30  16:23
08/11/21
08/11
16:23
08/11/21
16:23
BCEL

Atreca

$5.74 /

+0.04 (+0.70%)

 
ShowHide Related Items >><<
BCEL Atreca
$5.74 /

+0.04 (+0.70%)

BCEL Atreca
$5.74 /

+0.04 (+0.70%)

07/30/21 Wedbush
Atreca price target lowered to $12 from $27 at Wedbush
07/29/21 Stifel
Atreca price target lowered to $17 from $31 at Stifel
07/29/21 Roth Capital
Roth says rebound in Atreca shares may require presentation of added data
07/29/21 Stifel
Atreca selloff after preliminary ATRC-101 data appears overdone, says Stifel
BCEL Atreca
$5.74 /

+0.04 (+0.70%)

BCEL Atreca
$5.74 /

+0.04 (+0.70%)

Earnings
Atreca reports Q2 EPS (72c), consensus (69c) » 16:23
08/11/21
08/11
16:23
08/11/21
16:23
BCEL

Atreca

$5.74 /

+0.04 (+0.70%)

"We recently…

"We recently announced initial summary data from the dose escalation portion of the Phase 1b trial evaluating ATRC-101 in multiple solid tumors," said John Orwin, CEO. "ATRC-101 was well-tolerated in the study, and we believe that the initial signs of activity, which were associated with expression of ATRC-101's target, provide strong rationale for further evaluation. Additionally, we believe the data provide validation of the ability of our discovery platform to identify druggable tumor targets shared across broad groups of patients. We look forward to providing an update on our early-stage pipeline in the coming months as well as reporting additional monotherapy in 1H22, pembrolizumab combination data in mid-2022, and chemotherapy combination data in late 2022."

ShowHide Related Items >><<
BCEL Atreca
$5.74 /

+0.04 (+0.70%)

BCEL Atreca
$5.74 /

+0.04 (+0.70%)

07/30/21 Wedbush
Atreca price target lowered to $12 from $27 at Wedbush
07/29/21 Stifel
Atreca price target lowered to $17 from $31 at Stifel
07/29/21 Roth Capital
Roth says rebound in Atreca shares may require presentation of added data
07/29/21 Stifel
Atreca selloff after preliminary ATRC-101 data appears overdone, says Stifel
BCEL Atreca
$5.74 /

+0.04 (+0.70%)

BCEL Atreca
$5.74 /

+0.04 (+0.70%)

Recommendations
Atreca price target lowered to $12 from $27 at Wedbush » 08:04
07/30/21
07/30
08:04
07/30/21
08:04
BCEL

Atreca

$4.90 /

-3.31 (-40.32%)

Wedbush analyst Robert…

Wedbush analyst Robert Driscoll lowered the firm's price target on Atreca to $12 from $27 and keeps an Outperform rating on the shares. Atreca presented dose-escalation data for ATRC-101 from an ongoing Phase 1 study in patients with select solid tumors and while no clinical responses have been observed to date in the heavily pre-treated enrolled patients enrolled, Driscoll believes the initial biomarker data presented was consistent with the proposed ATRC-101 MOA, and supports significant potential for the ongoing combination cohort with anti PD-1 pembrolizumab, the analyst tells investors in a research note. He expects development to be focused going forward on combination studies.

ShowHide Related Items >><<
BCEL Atreca
$4.90 /

-3.31 (-40.32%)

BCEL Atreca
$4.90 /

-3.31 (-40.32%)

07/29/21 Stifel
Atreca price target lowered to $17 from $31 at Stifel
07/29/21 Roth Capital
Roth says rebound in Atreca shares may require presentation of added data
07/29/21 Stifel
Atreca selloff after preliminary ATRC-101 data appears overdone, says Stifel
06/03/21 Baird
Atreca tarnsferred with Outperform at Baird
BCEL Atreca
$4.90 /

-3.31 (-40.32%)

BCEL Atreca
$4.90 /

-3.31 (-40.32%)

Recommendations
Atreca price target lowered to $17 from $31 at Stifel » 15:19
07/29/21
07/29
15:19
07/29/21
15:19
BCEL

Atreca

$5.05 /

-3.16 (-38.49%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey lowered the firm's price target on Atreca to $17 from $31 and keeps a Buy rating on the shares. The analyst cites a fundamental change to estimates - including delayed launch timelines, more-conservative peak ATRC-101 sales estimates, and increased longer-term dilution associated with 2022-plus equity financing - and the likelihood sentiment is likely to remain materially unchanged in the absence of any additional, near-term data updates. Additionally, Willey says that he "still can't rationalize" Atreca shares trading at near-cash based upon a preliminary ATRC-101 data disclosure, a wholly-owned/earlier-stage pipeline of weaponized antibody candidates against both established/novel targets, and a platform technology-generated library of over 2K antibodies against non-autologous targets for which the accelerated pace of target deconvolution/identification should present future business development opportunity.

ShowHide Related Items >><<
BCEL Atreca
$5.05 /

-3.16 (-38.49%)

BCEL Atreca
$5.05 /

-3.16 (-38.49%)

07/29/21 Roth Capital
Roth says rebound in Atreca shares may require presentation of added data
07/29/21 Stifel
Atreca selloff after preliminary ATRC-101 data appears overdone, says Stifel
06/03/21 Baird
Atreca tarnsferred with Outperform at Baird
02/08/21 Jefferies
Atreca initiated with a Buy at Jefferies
BCEL Atreca
$5.05 /

-3.16 (-38.49%)

BCEL Atreca
$5.05 /

-3.16 (-38.49%)

Recommendations
Roth says rebound in Atreca shares may require presentation of added data » 12:56
07/29/21
07/29
12:56
07/29/21
12:56
BCEL

Atreca

$5.02 /

-3.19 (-38.86%)

After Atreca provided an…

After Atreca provided an initial update on the ongoing dose-escalating Phase I study of ATRC-101 in a variety of tumors, Roth Capital analyst Tony Butler noted that dose expansion trials and combination trials with pembrolizumab and separately with chemotherapy are continuing or will begin soon and that additional data will be presented in mid-2022. The analyst, who contends that a "rebound in the stock may require the presentation of these additional data," has a Buy rating and $30 price target on Atreca shares, which are down $3.10, or 38%, to $5.11 in afternoon trading.

ShowHide Related Items >><<
BCEL Atreca
$5.02 /

-3.19 (-38.86%)

BCEL Atreca
$5.02 /

-3.19 (-38.86%)

07/29/21 Stifel
Atreca selloff after preliminary ATRC-101 data appears overdone, says Stifel
06/03/21 Baird
Atreca tarnsferred with Outperform at Baird
02/08/21 Jefferies
Atreca initiated with a Buy at Jefferies
08/12/20 Stifel
Volatility in Atreca shares creates 'interesting' opportunity, says Stifel
BCEL Atreca
$5.02 /

-3.19 (-38.86%)

BCEL Atreca
$5.02 /

-3.19 (-38.86%)

Recommendations
Atreca selloff after preliminary ATRC-101 data appears overdone, says Stifel » 10:39
07/29/21
07/29
10:39
07/29/21
10:39
BCEL

Atreca

$5.33 /

-2.88 (-35.08%)

After Atreca reported…

After Atreca reported preliminary safety and efficacy data from the dose-escalation portion of the Phase 1b trial evaluating ATRC-101 in patients with advanced solid tumors known to be associated with greater than 50% target expression, Stifel analyst Stephen Willey said the data "appear to be consistent with management's prior characterization of this update," both in terms of what is being made available and what is likely to be observed. The analyst, who called it "extremely difficult to elucidate single-agent ATRC-101 activity in a small number of response-evaluable patients whom are heavily pre-treated," said he struggles to rationalize the stock's valuation at current levels "regardless of whether ATRC-101 proves viable over the longer-term." Citing his view on Atreca' sexpanding library of novel solid tumor targets and its scarcity value, Willey has a Buy rating on the shares, which are down $2.89, or 35%, to $5.32 in morning trading.

ShowHide Related Items >><<
BCEL Atreca
$5.33 /

-2.88 (-35.08%)

BCEL Atreca
$5.33 /

-2.88 (-35.08%)

06/03/21 Baird
Atreca tarnsferred with Outperform at Baird
02/08/21 Jefferies
Atreca initiated with a Buy at Jefferies
08/12/20 Stifel
Volatility in Atreca shares creates 'interesting' opportunity, says Stifel
BCEL Atreca
$5.33 /

-2.88 (-35.08%)

BCEL Atreca
$5.33 /

-2.88 (-35.08%)

Conference/Events
Atreca to hold a pharmaceutical update conference call » 07:55
07/29/21
07/29
07:55
07/29/21
07:55
BCEL

Atreca

$8.21 /

+0.57 (+7.46%)

Management holds a…

Management holds a conference call to present initial data from the dose escalation portion of the ongoing Phase 1b trial evaluating ATRC-101 will be held on July 29 at 8 am. Webcast Link

ShowHide Related Items >><<
BCEL Atreca
$8.21 /

+0.57 (+7.46%)

BCEL Atreca
$8.21 /

+0.57 (+7.46%)

06/03/21 Baird
Atreca tarnsferred with Outperform at Baird
02/08/21 Jefferies
Atreca initiated with a Buy at Jefferies
08/12/20 Stifel
Volatility in Atreca shares creates 'interesting' opportunity, says Stifel
BCEL Atreca
$8.21 /

+0.57 (+7.46%)

BCEL Atreca
$8.21 /

+0.57 (+7.46%)

Hot Stocks
Atreca presents initial clinical data from Phase 1b trial of ATRC-101 » 07:32
07/29/21
07/29
07:32
07/29/21
07:32
BCEL

Atreca

$8.21 /

+0.57 (+7.46%)

Atreca announced initial…

Atreca announced initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types that displayed greater than 50% target expression in preclinical studies. The Phase 1b trial is a first-in-human, open-label study of ATRC-101 in patients with select solid tumor cancers, utilizing a 3+3 design for the dose escalation portion. The objectives of the study are to characterize safety, determine a maximum tolerated or recommended dose for expansion, measure initial clinical activity, and characterize potential biomarkers of activity in tumors, plasma, and peripheral blood mononuclear cells. A total of 26 participants had been dosed in the trial as of the data cut-off date of July 16th, including 24 participants treated at five once-every-21-day dose levels, and two participants treated at one once-every-14-day dose level. The peak concentration of ATRC-101 was dose proportional and minimal accumulation was observed following multiple doses. ATRC-101's half-life was 10.5 days and was relatively consistent across all dose levels. ATRC-101 was generally well-tolerated, with no dose-limiting toxicities at doses less than or equal to 30 mg/kg. Respiratory failure and sepsis were the only grade greater than or equal to 3 AEs observed in more than one participant, and the one grade 4 treatment-emergent AE observed was a case of acute respiratory failure. The most common treatment-related AEs were fatigue, nausea, and tumor pain. Phase 1b monotherapy dose expansion is ongoing at 30 mg/kg, a combination study evaluating ATRC-101 with pembrolizumab is active and another combination study with pegylated liposomal doxorubicin is expected to begin enrolling patients in 4Q21. Atreca expects to report additional monotherapy data by mid-2022, pembrolizumab combination data in mid-2022 and chemotherapy combination data in late 2022. Supported by data from the dose escalation portion of the trial, Atreca is developing a diagnostic to select patients based on target expression

ShowHide Related Items >><<
BCEL Atreca
$8.21 /

+0.57 (+7.46%)

06/03/21 Baird
Atreca tarnsferred with Outperform at Baird
02/08/21 Jefferies
Atreca initiated with a Buy at Jefferies
08/12/20 Stifel
Volatility in Atreca shares creates 'interesting' opportunity, says Stifel
BCEL Atreca
$8.21 /

+0.57 (+7.46%)

BCEL Atreca
$8.21 /

+0.57 (+7.46%)

Conference/Events
Atreca to hold a pharmaceutical update conference call » 04:55
07/29/21
07/29
04:55
07/29/21
04:55
BCEL

Atreca

$8.21 /

+0.57 (+7.46%)

Management holds a…

Management holds a conference call to present initial data from the dose escalation portion of the ongoing Phase 1b trial evaluating ATRC-101 will be held on July 29 at 8 am. Webcast Link

ShowHide Related Items >><<
BCEL Atreca
$8.21 /

+0.57 (+7.46%)

06/03/21 Baird
Atreca tarnsferred with Outperform at Baird
02/08/21 Jefferies
Atreca initiated with a Buy at Jefferies
08/12/20 Stifel
Volatility in Atreca shares creates 'interesting' opportunity, says Stifel
BCEL Atreca
$8.21 /

+0.57 (+7.46%)

BCEL Atreca
$8.21 /

+0.57 (+7.46%)

Conference/Events
Atreca to hold a pharmaceutical update conference call » 15:39
07/27/21
07/27
15:39
07/27/21
15:39
BCEL

Atreca

$7.66 /

+0.225 (+3.03%)

Management holds a…

Management holds a conference call to present initial data from the dose escalation portion of the ongoing Phase 1b trial evaluating ATRC-101 will be held on July 29 at 8 am. Webcast Link

ShowHide Related Items >><<
BCEL Atreca
$7.66 /

+0.225 (+3.03%)

06/03/21 Baird
Atreca tarnsferred with Outperform at Baird
02/08/21 Jefferies
Atreca initiated with a Buy at Jefferies
08/12/20 Stifel
Volatility in Atreca shares creates 'interesting' opportunity, says Stifel
BCEL Atreca
$7.66 /

+0.225 (+3.03%)

BCEL Atreca
$7.66 /

+0.225 (+3.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.